Phosphorylation of PBK at Thr9 by CDK5 correlates with invasion of prolactinomas
CNS Neuroscience &Therapeutics, Volume 30, Issue 2, February 2024.The level of pPBK‐T9 is highly expressed in invasive PitNETs, CDK5 could promote the phosphorylation of PBK‐T9 through the p38 MAPK signaling pathway to promote cell proliferation and EMT progression. we revealed that this signaling axis in PitNETs, CDK5/PBK/p38 MAPK, promoted the tumorigenesis of PitNETs.
Qiuyue Fang +5 more
wiley +1 more source
Surgery as first-line treatment for prolactinoma? : Discussion of the literature and results of a consecutive series of surgically treated patients [PDF]
, 2023 Initial treatment for prolactinoma is usually conservative with dopamine agonists. However, the duration of treatment is often lifelong and can be associated with significant side effects.
Ringel, Florian +3 more
core +2 more sources
Idiopathic Granulomatous Mastitis
The Breast Journal, Volume 2024, Issue 1, 2024.Idiopathic granulomatous mastitis (IGM) is a rare, benign inflammatory disorder of the breast that is often underrecognized. The exact etiology and pathophysiology are unknown, but milk stasis is felt to play a role. Classically, this condition is noninfectious, but many cases are noted to be associated with Corynebacterium species.
Christina Dilaveri +6 more
wiley +1 more source
The efficacy of dopamine agonist therapy in a young man with a giant prolactinoma: case report [PDF]
, 2017 Prolactinomas are the most common of hormone secreting pituitary adenomas. Patients with prolactinomas generally have a benign prognosis. An algorithm is currently available for managing of this disease.
Alexandr I. Tsiberkin +3 more
core +1 more source
Rapid Improvement of Visual Field Defect with Medical Treatment in Giant Prolactinoma with Optic Nerve Compression [PDF]
Introduction: Prolactinomas are the most common form of pituitary adenomas of which micro-prolactinomas comprise of 90% and measure less than 1 cm and occur mostly in women.
Sharma, Sapna +2 more
core +1 more source
Giant prolactinoma: the sound of silence
Endocrinology Studies, 2014 Prolactinomas typically present with oligoamenorrhea or galactorrhea in woman and headaches, visual changes or impotence in men with auditory symptoms being a rare presentation. We describe a case of a man who presented with bilateral hearing loss and was found to have a giant prolactinoma.
Shira R. Saul, Maya P. Raghuwanshi
openaire +1 more source
Aripiprazole use as a cause of dopamine agonist failure in the treatment of prolactinomas
Endocrine OncologyProlactinomas are the most common hypersecretory pituitary adenoma. The traditional first-line therapy is dopamine agonists (DAs), which are highly effective and tolerated in the majority of cases.
Edward Mignone +4 more
doaj +1 more source
Restoration of fertility in a woman with giant prolactinoma in response to cabergoline treatment
Endocrinology, Diabetes & Metabolism Case Reports, 2019 A 32-year-old woman presented with primary amenorrhoea, prolactin (PRL) level of 154 150 mIU/L and was diagnosed with a giant pituitary adenoma measuring maximum 6.2 cm.
L I Astaf’eva +5 more
doaj +1 more source
Clinical Outcome of Invasive Pituitary Prolactinomas Treated with Cabergoline
مجله كليه طب الكندي, 2020 Background: Treatment of invasive prolactinoma, which has several characteristics including invasive growth into cavernous sinuses and formation of giant adenomas compressing adjacent neural structures, resulting in neurological dysfunction, has been ...
Bassam M Flamerz Arkawazi
doaj +1 more source
Journal of Clinical & Translational EndocrinologyObjectives: Dopamine agonists serve as first-line therapies for most giant prolactinomas. The objective of this study was to assess the differential impact of dopamine agonist dosing strategies on biochemical (prolactin normalisation) and radiological ...
Hána Václav Jr. +11 more
doaj +1 more source